The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 6, 2001, Pages 308-331

  Hahn, Theresa ^a   Wolff, Steven N ^b   Czuczman, Myron ^a   Fisher, Richard ^c   Lazarus, Hillard ^d   Vose, Julie ^e   Warren, Lisa ^f   Watt, Richard ^g   McCartby Jr , Philip L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f Lymphoma Research Foundation   (United States)

^g United Resource Networks   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BETA 2 MICROGLOBULIN; CARMUSTINE; CD20 ANTIGEN; CD24 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CISPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FOLINATE CALCIUM; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; RITUXIMAB; UNINDEXED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EXPERT SYSTEM; GRAFT VERSUS HOST REACTION; HEALTH CARE MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PEER REVIEW; PRACTICE GUIDELINE; PROGNOSIS; SIDE EFFECT; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0034913034     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(01)80003-3     Document Type: Review

References (93)

1. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
2. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
3. Classification of non-Hodgkin's lymphomas
4. Updated Kiel classification for lymphomas
5. Tumors of the hematopoietic system
6. ASBMT policy statement regarding the methodology of evidence-based reviews in evaluating the role of blood and marrow transplantation in the treatment of selected disease
7. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
8. Parma International Protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation
9. PARMA international protocol: Pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)
10. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial
11. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma
12. Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: Are trial results generalized to other patient populations?
13. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic subgroups
14. Salvage therapy with Pro-MACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP
15. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age
16. Factors influencing the outcome of autologous stem cell transplant at first-sensitive relapse in 247 adults with diffuse large-cell lymphoma
17. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: Clinical impact of immunophenotype and in vitro purging
18. Rituxan before and after high dose chemotherapy (HDC) with stem cell support for relapsed aggressive lymphoma
19. High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma
20. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation
21. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A Southwest Oncology Group Study
22. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma
23. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens- a Southwest Oncology Group trial
24. High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow
25. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine and etoposide
26. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy
27. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide and cyclophosphamide and autologous bone marrow transplantation
28. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
29. High dose therapy with autologous stem cell support in 366 patients with large cell lymphoma. A retrospective analysis of the GEL/TAMO Spanish cooperative group
30. Fractionated total-body irradiation, etoposide and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma
31. Primary diffuse large B-cell lymphoma of the mediastinum: Outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation
32. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: Mediastinal localization predicts for a favorable outcome
33. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin's lymphoma: An intention-to-treat analysis
34. High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: Pattern of failure and implications for involved-field radiotherapy
35. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
36. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: A single-center study of 22 patients
37. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma
38. Ancestim (r-metHu Stem Cell Factor, SCF) in combination with Filgrastim can mobilize sufficient peripheral blood progenitor cells (PBPC) to support high dose salvage chemotherapy and late intensification in aggressive non-Hodgkin's lymphoma
39. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology
40. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon
41. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: Toxicity and antitumor activity in 26 patients with poor-risk malignancies
42. High-dose chemotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study
43. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients
44. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
45. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 Protocol - A Groupe d'Etude des Lymphomes de l'Adulte study
46. A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission
47. Role of high-dose therapy and initial response in survival of poor risk patients with aggressive non-Hodgkin's lymphoma: A retrospective series on 126 patients from a single center
48. Early Autologous stem cell transplantation (ASCT) versus conventional first line chemotherapy in high-risk aggressive Non Hodgkin's lymphoma (NHL): An Italian multicenter randomized trial
49. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
50. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL)
51. Early autologous stem cell transplantation as first-line therapy in poor prognosis non-Hodgkin's lymphoma (NHL): An Italian randomized trial
52. Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: Updated results of the randomized LNH93-3 study
53. Up-front high-dose therapy and autologous peripheral blood progenitor cell transplantation versus standard CHOP chemotherapy in poor prognosis aggressive non-Hodgkin's lymphoma: A preliminary report
54. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group
55. Autologous stem cell transplantation for diffuse large cell lymphoma: Analysis of 797 cases referred to the EBMT registry
56. Autologous stem cell transplantation (ASCT) for mediastinal large B-cell lymphoma with sclerosis (MLBCL)
57. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle
58. Bone Marrow involvement in patients with diffuse large cell lymphoma (DLCL) undergoing autologous transplantation
59. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
60. on behalf of the Intergruppo Italiano Linfomi (ILL)
61. BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma
62. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma
63. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma
64. A GOELAMS trial. Frontline high-dose chemotherapy (HDC) with autologous stem cell transplantation compared to standard CHOP regimen: A randomized trial for adult patients with non IPI high-risk intermediate or high (NHL)
65. VACOP-B, high dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co-operative Study Group
66. for the GELA. Double autotransplant (DAT) as first line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 31 patients
67. Three step high-dose chemotherapy in poor prognosis non-Hodgkin's lymphoma
68. Three step high-dose chemotherapy in intermediate risk non-Hodgkin's lymphoma
69. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas
70. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
71. Diffuse large B cell lymphoma outcome prediction by gene expression profiling
72. Incidence and clinical correlations of BCL6 5′ mutations in B-cell diffuse large cell lymphoma (B-DLCL)
73. A subset of non-immunoblastic diffuse large B-cell lymphomas with highly aggressive clinical course co-expresses Bcl-2 and P-glycoprotein
74. Prognostic significance of survivin expression in diffuse large B-cell lymphomas
75. Serum β-2 microglobulin improves the prognostic discrimination of the International Prognostic Index (IPI)
76. Comparison of prognostic models for diffuse large B cell lymphomas (DLC): Can β2-microglobulin (β2M) improve upon the International Prognostic Index (IPI)?
77. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
78. Clinical relevance of BCL2, BCL6 and MYC rearrangements in diffuse large B-cell lymphoma
79. High levels of serum CD44 are correlated with poor prognosis in malignant lymphoma
80. P53 mutation and protein expression and analysis of outcome in nodal diffuse large B cell lymphoma
81. Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphoma
82. Proliferative activity in aggressive non-Hodgkin's lymphomas: An immunohistochemical study with MIB-1 antibody of 991 cases from the GELA-LNH87 trial
83. Interferon α2b versus no treatment after intensive therapy and autologous stem cell transplantation for relapsing lymphoma. Preliminary results of an international randomized study on 174 patients
84. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma
85. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma
86. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry data
87. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients
88. Randomized trial of peripheral blood progenitor cell vs. bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: A clinical and molecular analysis
89. Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: A prospective, comparative trial
90. Randomized trials of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients
91. Peripheral-blood stem-cell transplantation in Hodgkin's and non-Hodgkin's lymphomas: A new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data
92. Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: A case-controlled analysis of the EBMT Registry data